Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) is among the best US stocks under $10 to invest in. Catherine Novack, an analyst at JonesTrading, has raised the price target on Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) to $9.00 from $6.00, while reaffirming a Buy rating on the stock. This potential upside of about 66.98% from the current price reflects the company’s strong position following FDA approval of its NDA resubmission.
Earlier on July 17, 2025, Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) announced that the U.S. Food and Drug Administration (FDA) accepted for review the company’s resubmitted New Drug Application (NDA) for its lead product, Reproxalap, aimed at the ophthalmic disorder dry eye disease. The regulatory authority has set December 16, 2025, as the target action date under the Prescription Drug User Fee Act (PDUFA) for completing its review.
A medical researcher in a laboratory focusing on a diagnosis of an ocular disease.
This is when things get interesting. AbbVie is anticipated to pay $100 million upfront and share US profits if the approval is granted, which many believe will mitigate the risks associated with commercialization. The platform offered by Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) also includes follow-on assets like ADX-629 and ADX-2191.
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) is a Massachusetts-based biotechnology company that engages in solutions aimed at immune-mediated and metabolic diseases. Incorporated in 2004, the company is committed to enhancing the patient’s well-being.
While we acknowledge the potential of ALDX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.
